MICOS13

Across TCGA pan-cancer cohorts, MICOS13 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MICOS13 data layer compared with 26 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher MICOS13 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated MICOS13 expression acts as an unfavorable survival marker, although some lineages such as PDAC and COAD show a favorable association.

PDAC, LSCC, and COAD are the cancer types where MICOS13 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	II,III,IV	0.838	0.673	<.001	38	view →
LSCC	DFS	Tertile	III,IV	0.421	1.000	.007	17	view →
COAD	DFS	Median	All	1.000	0.923	.020	6	view →
CCRCC	DFS	Median	III,IV	1.000	0.451	.032	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

MICOS13–PDAC (DFS)

Open the PDAC breakdown →